Mesenchymal stromal cells and rheumatic diseases: New tools from pathogenesis to regenerative therapies

Cytotherapy

Volumn 17, Issue 7, 2015, Pages 832-849

  Cipriani, Paola ^a   Ruscitti, Piero ^a   Di Benedetto, Paola ^a   Carubbi, Francesco ^a   Liakouli, Vasiliki ^a   Berardicurti, Onorina ^a   Ciccia, Francesco ^b   Triolo, Giovanni ^b   Giacomelli, Roberto ^a  

^a UNIVERSITY OF L'AQUILA   (Italy)

^b UNIVERSITY OF PALERMO   (Italy)

Author keywords

Mesenchymal stromal cells; Pathogenesis; Regenerative therapy; Rheumatic disease

Indexed keywords

AGGRECANASE; CHONDROITIN SULFATE; CYCLOPHOSPHAMIDE; DEXAMETHASONE; GLUCOSAMINE; MATRIX METALLOPROTEINASE; NITRIC OXIDE; NONSTEROID ANTIINFLAMMATORY AGENT; OMEGA 3 FATTY ACID; PROSTAGLANDIN; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR ALPHA ANTIBODY;

ARTHROTOMY; ARTICULAR CARTILAGE; BIODEGRADABILITY; CELL CYCLE ARREST; CELL REGENERATION; CLINICAL FEATURE; DISEASE SEVERITY; FEMUR HEAD NECROSIS; HUMAN; MESENCHYMAL STROMA CELL; MORTALITY; NONHUMAN; OSTEOARTHRITIS; OSTEOGENESIS IMPERFECTA; OSTEOPHYTE; OSTEOPOROSIS; OUTCOME ASSESSMENT; PATHOGENESIS; PERIOSTEUM; PHENOTYPE; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; PROTEIN SECRETION; REVIEW; RHEUMATOID ARTHRITIS; SYNOVIUM; SYSTEMIC LUPUS ERYTHEMATOSUS; SYSTEMIC SCLEROSIS; TIBIA OSTEOTOMY; VISCOSUPPLEMENTATION; ADULT; AUTOIMMUNE DISEASES; BIOLOGICAL THERAPY; BONE MARROW; BONE MARROW CELL; CARTILAGE CELL; CELL DIFFERENTIATION; CYTOLOGY; MESENCHYMAL STEM CELL TRANSPLANTATION; OSTEOBLAST; PATHOLOGY; PHYSIOLOGY; PROCEDURES; REGENERATIVE MEDICINE; RHEUMATIC DISEASES;

ADULT; AUTOIMMUNE DISEASES; BONE MARROW; BONE MARROW CELLS; CELL DIFFERENTIATION; CELL- AND TISSUE-BASED THERAPY; CHONDROCYTES; HUMANS; MESENCHYMAL STEM CELL TRANSPLANTATION; MESENCHYMAL STROMAL CELLS; OSTEOBLASTS; REGENERATIVE MEDICINE; RHEUMATIC DISEASES;

EID: 84938072379     PISSN: 14653249     EISSN: 14772566     Source Type: Journal    
DOI: 10.1016/j.jcyt.2014.12.006     Document Type: Review

References (148)

1. Dominici M., Le Blanc K., Mueller I., Slaper-Cortenbach I., Marini F., Krause D., et al. Minimal criteria for defining multipotent mesenchymal stromal cells. The International Society for Cellular Therapy position statement. Cytotherapy 2006, 8:315-317.
2. Djouad F., BouffiC., Ghannam S., Noël D., Jorgensen C. Mesenchymal stem cells: innovative therapeutic tools for rheumatic diseases. Nat Rev Rheumatol 2009, 5:392-399.
3. Rehman J., Traktuev D., Li J., Merfeld-Clauss S., Temm-Grove C.J., Bovenkerk J.E., et al. Secretion of angiogenic and antiapoptotic factors by human adipose stromal cells. Circulation 2004, 109:1292-1298.
4. Bartholomew A., Sturgeon C., Siatskas M., Ferrer K., McIntosh K., Patil S., et al. Mesenchymal stem cells suppress lymphocyte proliferation in vitro and prolong skin graft survival in vivo. Exp Hematol 2002, 30:42-48.
5. Ben-Ami E., Berrih-Aknin S., Miller A. Mesenchymal stem cells as an immunomodulatory therapeutic strategy for autoimmune diseases. Autoimmun Rev 2011, 10:410-415.
6. Cipriani P., Carubbi F., Liakouli V., Marrelli A., Perricone C., Perricone R., et al. Stem cells in autoimmune diseases: Implications for pathogenesis and future trends in therapy. Autoimmun Rev 2013, 12:709-716.
7. Bocelli-Tyndall C., Bracci L., Spagnoli G., Braccini A., Bouchenaki M., Ceredig R., et al. Bone marrow mesenchymal stromal cells (BM-MSCs) from healthy donors and auto-immune disease patients reduce the proliferation of autologous- and allogeneic-stimulated lymphocytes in vitro. Rheumatology (Oxford) 2007, 46:403-408.
8. Krampera M., Glennie S., Dyson J., Scott D., Laylor R., Simpson E., et al. Bone marrow mesenchymal stem cells inhibit the response of naive and memory antigen-specific T cells to their cognate peptide. Blood 2003, 101:3722-3729.
9. Dominici M., Paolucci P., Conte P., Horwitz E.M. Heterogeneity of multipotent mesenchymal stromal cells: from stromal cells to stem cells and vice versa. Transplantation 2009, 87(9 Suppl):S36-42.
10. van Laar J.M., Tyndall A. Adult stem cells in the treatment of autoimmune diseases. Rheumatology (Oxford) 2006, 45:1187-1193.
11. Di Nicola M., Carlo-Stella C., Magni M., Milanesi M., Longoni P.D., Matteucci P., et al. Human bone marrow stromal cells suppress T-lymphocyte proliferation induced by cellular or nonspecific mitogenic stimuli. Blood 2002, 99:3838-3843.
12. Zappia E., Casazza S., Pedemonte E., Benvenuto F., Bonanni I., Gerdoni E., et al. Mesenchymal stem cells ameliorate experimental autoimmune encephalomyelitis inducing T-cell anergy. Blood 2005, 106:1755-1761.
13. Rafei M., Campeau P.M., Aguilar-Mahecha A., Buchanan M., Williams P., Birman E., et al. Mesenchymal stromal cells ameliorate experimental autoimmune encephalomyelitis by inhibiting CD4 Th17 T cells in a CC chemokine ligand 2-dependent manner. J Immunol 2009, 182:5994-6002.
14. Constantin G., Marconi S., Rossi B., Angiari S., Calderan L., Anghileri E., et al. Adipose-derived mesenchymal stem cells ameliorate chronic experimental autoimmune encephalomyelitis. Stem Cells 2009, 27:2624-2635.
15. Buckwalter J.A., Martin J.A. Osteoarthritis. Adv Drug Deliv Rev 2006, 58:150-167.
16. Lawrence R.C., Felson D.T., Helmick C.G., Arnold L.M., Choi H., Deyo R.A., et al. Estimates of the prevalence of arthritis and other rheumatic conditions in the United States. Part II. Arthritis Rheum 2008, 58:26-35.
17. Gore M., Tai K.S., Sadosky A., Leslie D., Stacey B.R. Clinical comorbidities, treatment patterns, and direct medical costs of patients with osteoarthritis in usual care: a retrospective claims database analysis. J Med Econ 2011, 14:497-507.
18. McKenna M.T., Michaud C.M., Murray C.J., Marks J.S. Assessing the burden of disease in the United States using disability-adjusted life years. Am J Prev Med 2005, 28:415-423.
19. Guilak F. Biomechanical factors in osteoarthritis. Best Pract Res Clin Rheumatol 2011, 25:815-823.
20. Goldring M.B., Goldring S.R. Articular cartilage and subchondral bone in the pathogenesis of osteoarthritis. Ann N Y Acad Sci 2010, 1192:230-237.
21. Stone A.V., Loeser R.F., Vanderman K.S., Long D.L., Clark S.C., Ferguson C.M. Pro-inflammatory stimulation of meniscus cells increases production of matrix metalloproteinases and additional catabolic factors involved in osteoarthritis pathogenesis. Osteoarthritis Cartilage 2014, 22:264-274.
22. de Lange-Brokaar B.J., Ioan-Facsinay A., van Osch G.J., Zuurmond A.M., Schoones J., Toes R.E., et al. Synovial inflammation, immune cells and their cytokines in osteoarthritis: a review. Osteoarthritis Cartilage 2012, 20:1484-1499.
23. Ayral X., Pickering E.H., Woodworth T.G., Mackillop N., Dougados M. Synovitis: a potential predictive factor of structural progression of medial tibiofemoral knee osteoarthritis - results of a 1 year longitudinal arthroscopic study in 422 patients. Osteoarthritis Cartilage 2005, 13:361-367.
24. Benito M.J., Veale D.J., FitzGerald O., van den Berg W.B., Bresnihan B. Synovial tissue inflammation in early and late osteoarthritis. Ann Rheum Dis 2005, 64:1263-1267.
25. Barry F., Murphy M. Mesenchymal stem cells in joint disease and repair. Nat Rev Rheumatol 2013, 9:584-594.
26. nd edition. J Am Acad Orthop Surg 2013, 21:571-576.
27. De Bari C., Dell'Accio F., Tylzanowski P., Luyten F.P. Multipotent mesenchymal stem cells from adult human synovial membrane. Arthritis Rheum 2001, 44:1928-1942.
28. Jones E.A., Crawford A., English A., Henshaw K., Mundy J., Corscadden D., et al. Synovial fluid mesenchymal stem cells in health and early osteoarthritis: detection and functional evaluation at the single-cell level. Arthritis Rheum 2008, 58:1731-1740.
29. Khan W.S., Adesida A.B., Tew S.R., Longo U.G., Hardingham T.E. Fat pad-derived mesenchymal stem cells as a potential source for cell-based adipose tissue repair strategies. Cell Prolif 2012, 45:111-120.
30. Dowthwaite G.P., Bishop J.C., Redman S.N., Khan I.M., Rooney P., Evans D.J., et al. The surface of articular cartilage contains a progenitor cell population. J Cell Sci 2004, 117:889-897.
31. Huang T.F., Chen Y.T., Yang T.H., Chen L.L., Chiou S.H., Tsai T.H., et al. Isolation and characterization of mesenchymal stromal cells from human anterior cruciate ligament. Cytotherapy 2008, 10:806-814.
32. Segawa Y., Muneta T., Makino H., Nimura A., Mochizuki T., Ju Y.J., et al. Mesenchymal stem cells derived from synovium, meniscus, anterior cruciate ligament, and articular chondrocytes share similar gene expression profiles. J Orthop Res 2009, 27:435-441.
33. Murphy J.M., Dixon K., Beck S., Fabian D., Feldman A., Barry F. Reduced chondrogenic and adipogenic activity of mesenchymal stem cells from patients with advanced osteoarthritis. Arthritis Rheum 2002, 46:704-713.
34. Scharstuhl A., Schewe B., Benz K., Gaissmaier C., Bühring H.J., Stoop R. Chondrogenic potential of human adult mesenchymal stem cells is independent of age or osteoarthritis etiology. Stem Cells 2007, 25:3244-3251.
35. Im G.I., Jung N.H., Tae S.K. Chondrogenic differentiation of mesenchymal stem cells isolated from patients in late adulthood: the optimal conditions of growth factors. Tissue Eng 2006, 12:527-536.
36. Coutu D.L., François M., Galipeau J. Inhibition of cellular senescence by developmentally regulated FGF receptors in mesenchymal stem cells. Blood 2011, 117:6801-6812.
37. De Bari C., Dell'Accio F., Luyten F.P. Human periosteum-derived cells maintain phenotypic stability and chondrogenic potential throughout expansion regardless of donor age. Arthritis Rheum 2001, 44:85-95.
38. Jones E., English A., Churchman S.M., Kouroupis D., Boxall S.A., Kinsey S., et al. Large-scale extraction and characterization of CD271+ multipotential stromal cells from trabecular bone in health and osteoarthritis: implications for bone regeneration strategies based on uncultured or minimally cultured multipotential stromal cells. Arthritis Rheum 2010, 62:1944-1954.
39. Hiraoka K., Grogan S., Olee T., Lotz M. Mesenchymal progenitor cells in adult human articular cartilage. Biorheology 2006, 43:447-454.
40. Koelling S., Kruegel J., Irmer M., Path J.R., Sadowski B., Miro X., et al. Migratory chondrogenic progenitor cells from repair tissue during the later stages of human osteoarthritis. Cell Stem Cell 2009, 4:324-335.
41. Stanton H., Rogerson F.M., East C.J., Golub S.B., Lawlor K.E., Meeker C.T., et al. ADAMTS5 is the major aggrecanase in mouse cartilage in vivo and in vitro. Nature 2005, 434:648-652.
42. Glasson S.S., Askew R., Sheppard B., Carito B., Blanchet T., Ma H.L., et al. Deletion of active ADAMTS5 prevents cartilage degradation in a murine model of osteoarthritis. Nature 2005, 434:644-648.
43. Wang V.M., Bell R.M., Thakore R., Eyre D.R., Galante J.O., Li J., et al. Murine tendon function is adversely affected by aggrecan accumulation due to the knockout of ADAMTS5. J Orthop Res 2012, 30:620-626.
44. Velasco J., Li J., DiPietro L., Stepp M.A., Sandy J.D., Plaas A. Adamts5 deletion blocks murine dermal repair through CD44-mediated aggrecan accumulation and modulation of transforming growth factor β1 (TGFβ1) signaling. J Biol Chem 2011, 286:26016-26027.
45. Ameye L.G., Young M.F. Animal models of osteoarthritis: lessons learned while seeking the "Holy Grail". Curr Opin Rheumatol 2006, 18:537-547.
46. Nöth U., Steinert A.F., Tuan R.S. Technology insight: adult mesenchymal stem cells for osteoarthritis therapy. Nat Clin Pract Rheumatol 2008, 4:371-380.
47. Murphy J.M., Fink D.J., Hunziker E.B., Barry F.P. Stem cell therapy in a caprine model of osteoarthritis. Arthritis Rheum 2003, 48:3464-3474.
48. Liu Y., Wu J., Zhu Y., Han J. Therapeutic application of mesenchymal stem cells in bone and joint diseases. Clin Exp Med 2014, 14:13-24.
49. Lee C.H., Cook J.L., Mendelson A., Moioli E.K., Yao H., Mao J.J. Regeneration of the articular surface of the rabbit synovial joint by cell homing: a proof of concept study. Lancet 2010, 376:440-448.
50. Johnson K., Zhu S., Tremblay M.S., Payette J.N., Wang J., Bouchez L.C., et al. A stem cell-based approach to cartilage repair. Science 2012, 336:717-721.
51. Wang Y., Belflower R.M., Dong Y.F., Schwarz E.M., O'Keefe R.J., Drissi H. Runx1/AML1/Cbfa2 mediates onset of mesenchymal cell differentiation toward chondrogenesis. J Bone Miner Res 2005, 20:1624-1636.
52. Wotton S., Terry A., Kilbey A., Jenkins A., Herzyk P., Cameron E., et al. Gene array analysis reveals a common Runx transcriptional programme controlling cell adhesion and survival. Oncogene 2008, 27:5856-5866.
53. Black L.L., Gaynor J., Gahring D., Adams C., Aron D., Harman S., et al. Effect of adipose-derived mesenchymal stem and regenerative cells on lameness in dogs with chronicosteoarthritis of the coxofemoral joints: a randomized, double-blinded, multicenter, controlled trial. Vet Ther 2007, 8:272-284.
54. Black L.L., Gaynor J., Adams C., Dhupa S., Sams A.E., Taylor R., et al. Effect of intraarticular injection of autologous adipose-derived mesenchymal stem and regenerative cells on clinical signs of chronic osteoarthritis of the elbow joint in dogs. Vet Ther 2008, 9:192-200.
55. Fan C.G., Zhang Q.J., Zhou J.R. Therapeutic potentials of mesenchymal stem cells derived from human umbilical cord. Stem Cell Rev 2011, 7:195-207.
56. Wang L., Tran I., Seshareddy K., Weiss M.L., Detamore M.S. A comparison of human bone marrow-derived mesenchymal stem cells and human umbilical cord-derived mesenchymal stromal cells for cartilage tissue engineering. Tissue Eng Part A 2009, 15:2259-2266.
57. Fong C.Y., Subramanian A., Gauthaman K., Venugopal J., Biswas A., Ramakrishna S., et al. Human umbilical cord Wharton's jelly stem cells undergo enhanced chondrogenic differentiation when grown on nanofibrous scaffolds and in a sequential two-stage culture medium environment. Stem Cell Rev 2012, 8:195-209.
58. Wakitani S., Imoto K., Yamamoto T., Saito M., Murata N., Yoneda M. Human autologous culture expanded bone marrow mesenchymal cell transplantation for repair of cartilage defects in osteoarthritic knees. Osteoarthritis Cartilage 2002, 10:199-206.
59. Pak J. Regeneration of human bones in hip osteonecrosis and human cartilage in knee osteoarthritis with autologous adipose-tissue-derived stem cells: a case series. J Med Case Rep 2011, 5:296.
60. McInnes I.B., Schett G. The pathogenesis of rheumatoid arthritis. N Engl J Med 2011, 365:2205-2219.
61. Dudics V., Kunstár A., Kovács J., Lakatos T., Géher P., Gömör B., et al. Chondrogenic potential of mesenchymal stem cells from patients with rheumatoid arthritis and osteoarthritis: measurements in a microculture system. Cells Tissues Organs 2009, 189:307-316.
62. Jones E., Churchman S.M., English A., Buch M.H., Horner E.A., Burgoyne C.H., et al. Mesenchymal stem cells in rheumatoid synovium: enumeration and functional assessment in relation to synovial inflammation level. Ann Rheum Dis 2010, 69:450-457.
63. Marinova-Mutafchieva L., Williams R.O., Funa K., Maini R.N., Zvaifler N.J. Inflammation is preceded by tumor necrosis factor-dependent infiltration of mesenchymal cells in experimental arthritis. Arthritis Rheum 2002, 46:507-513.
64. Li X., Makarov S.S. An essential role of NF-kappaB in the "tumor-like" phenotype of arthritic synoviocytes. Proc Natl Acad Sci USA 2006, 103:17432-17437.
65. Djouad F., Fritz V., Apparailly F., Louis-Plence P., Bony C., Sany J., et al. Reversal of the immunosuppressive properties of mesenchymal stem cells by tumor necrosis factor alpha in collagen-induced arthritis. Arthritis Rheum 2005, 52:1595-1603.
66. Augello A., Tasso R., Negrini S.M., Cancedda R., Pennesi G. Cell therapy using allogeneic bone marrow mesenchymal stem cells prevents tissue damage in collagen-induced arthritis. Arthritis Rheum 2007, 56:1175-1186.
67. González M.A., Gonzalez-Rey E., Rico L., Büscher D., Delgado M. Treatment of experimental arthritis by inducing immune tolerance with human adipose-derived mesenchymal stem cells. Arthritis Rheum 2009, 60:1006-1019.
68. Yañez R., Lamana M.L., García-Castro J., Colmenero I., Ramírez M., Bueren J.A. Adipose tissue-derived mesenchymal stem cells have in vivo immunosuppressive properties applicable for the control of the graft-versus-host disease. Stem Cells 2006, 24:2582-2591.
69. Chen B., Hu J., Liao L., Sun Z., Han Q., Song Z., et al. Flk-1+ mesenchymal stem cells aggravate collagen-induced arthritis by up-regulating interleukin-6. Clin Exp Immunol 2010, 159:292-302.
70. Schurgers E., Kelchtermans H., Mitera T., Geboes L., Matthys P. Discrepancy between the in vitro and in vivo effects of murine mesenchymal stem cells on T-cell proliferation and collagen-induced arthritis. Arthritis Res Ther 2010, 12:R31.
71. Gonzalez-Rey E., Gonzalez M.A., Varela N., O'Valle F., Hernandez-Cortes P., Rico L., et al. Human adipose-derived mesenchymal stem cells reduce inflammatory and T cell responses and induce regulatory T cells in vitro in rheumatoid arthritis. Ann Rheum Dis 2010, 69:241-248.
72. Park M.J., Park H.S., Cho M.L., Oh H.J., Cho Y.G., Min S.Y., et al. Transforming growth factor β-transduced mesenchymal stem cells ameliorate experimental autoimmune arthritis through reciprocal regulation of Treg/Th17 cells and osteoclastogenesis. Arthritis Rheum 2011, 63:1668-1680.
73. Liu Y., Mu R., Wang S., Long L., Liu X., Li R., et al. Therapeutic potential of human umbilical cord mesenchymal stem cells in the treatment of rheumatoid arthritis. Arthritis Res Ther 2010, 12:R210.
74. El-Jawhari J.J., El-Sherbiny Y.M., Jones E.A., McGonagle D. Mesenchymal stem cells, autoimmunity and rheumatoid arthritis. QJM 2014, 107:505-514.
75. Tokano Y., Morimoto S., Amano H., Kawanishi T., Yano T., Tomyo M., et al. The relationship between initial clinical manifestation and long-term prognosis of patients with systemic lupus erythematosus. Mod Rheumatol 2005, 15:275-282.
76. Cervera R., Khamashta M.A., Font J., Sebastiani G.D., Gil A., Lavilla P., et al. Morbidity and mortality in systemic lupus erythematosus during a 5-year period. A multicenter prospective study of 1,000 patients. European Working Party on Systemic Lupus Erythematosus. Medicine (Baltimore) 1999, 78:167-175.
77. Ruiz-Irastorza G., Olivares N., Ruiz-Arruza I., Martinez-Berriotxoa A., Egurbide M.V., Aguirre C. Predictors of major infections in systemic lupus erythematosus. Arthritis Res Ther 2009, 11:R109.
78. Bernatsky S., Boivin J.F., Joseph L., Manzi S., Ginzler E., Gladman D.D., et al. Mortality in systemic lupus erythematosus. Arthritis Rheum 2006, 54:2550-2557.
79. Sui W., Hou X., Che W., Chen J., Ou M., Xue W., et al. Hematopoietic and mesenchymal stem cell transplantation for severe and refractory systemic lupus erythematosus. Clin Immunol 2013, 148:186-197.
80. Sun L.Y., Zhang H.Y., Feng X.B., Hou Y.Y., Lu L.W., Fan L.M. Abnormality of bone marrow-derived mesenchymal stem cells in patients with systemic lupus erythematosus. Lupus 2007, 16:121-128.
81. Tang Y., Ma X., Zhang H., Gu Z., Hou Y., Gilkeson G.S., et al. Gene expression profile reveals abnormalities of multiple signaling pathways in mesenchymal stem cell derived from patients with systemic lupus erythematosus. Clin Dev Immunol 2012, 2012:826182.
82. Gu Z., Cao X., Jiang J., Li L., Da Z., Liu H., et al. Upregulation of p16INK4A promotes cellular senescence of bone marrow-derived mesenchymal stem cells from systemic lupus erythematosus patients. Cell Signal 2012, 24:2307-2314.
83. Nie Y., Lau C., Lie A., Chan G., Mok M. Defective phenotype of mesenchymal stem cells in patients with systemic lupus erythematosus. Lupus 2010, 19:850-859.
84. Papadaki H.A., Boumpas D.T., Gibson F.M., Jayne D.R., Axford J.S., Gordon-Smith E.C., et al. Increased apoptosis of bone marrow CD34(+) cells and impaired function of bone marrow stromal cells in patients with systemic lupus erythematosus. Br J Haematol 2001, 115:167-174.
85. Heo J.Y., Jing K., Song K.S., Seo K.S., Park J.H., Kim J.S., et al. Downregulation of APE1/Ref-1 is involved in the senescence of mesenchymal stem cells. Stem Cells 2009, 27:1455-1462.
86. Ebert R., Ulmer M., Zeck S., Meissner-Weigl J., Schneider D., Stopper H., et al. Selenium supplementation restores the antioxidative capacity and prevents cell damage in bone marrow stromal cells in vitro. Stem Cells 2006, 24:1226-1235.
87. Maeda K., Malykhin A., Teague-Weber B.N., Sun X.H., Farris A.D., Coggeshall K.M. Interleukin-6 aborts lymphopoiesis and elevates production of myeloid cells in systemic lupus erythematosus-prone B6.Sle1.Yaa animals. Blood 2009, 113:4534-4540.
88. Essers M.A., Offner S., Blanco-Bose W.E., Waibler Z., Kalinke U., Duchosal M.A., et al. IFNalpha activates dormant haematopoietic stem cells in vivo. Nature 2009, 458:904-908.
89. Kang Y.J., Yang S.J., Park G., Cho B., Min C.K., Kim T.Y., et al. A novel function of interleukin-10 promoting self-renewal of hematopoietic stem cells. Stem Cells 2007, 25:1814-1822.
90. Pronk C.J., Veiby O.P., Bryder D., Jacobsen S.E. Tumor necrosis factor restricts hematopoietic stem cell activity in mice: involvement of two distinct receptors. J Exp Med 2011, 208:1563-1570.
91. Zhou K., Zhang H., Jin O., Feng X., Yao G., Hou Y., et al. Transplantation of human bone marrow mesenchymal stem cell ameliorates the autoimmune pathogenesis in MRL/lpr mice. Cell Mol Immunol 2008, 5:417-424.
92. Sun L., Akiyama K., Zhang H., Yamaza T., Hou Y., Zhao S., et al. Mesenchymal stem cell transplantation reverses multiorgan dysfunction in systemic lupus erythematosus mice and humans. Stem Cells 2009, 27:1421-1432.
93. Choi E.W., Shin I.S., Park S.Y., Park J.H., Kim J.S., Yoon E.J., et al. Reversal of serologic, immunologic, and histologic dysfunction in mice with systemic lupus erythematosus by long-term serial adipose tissue-derived mesenchymal stem cell transplantation. Arthritis Rheum 2012, 64:243-253.
94. Gu F., Molano I., Ruiz P., Sun L., Gilkeson G.S. Differential effect of allogeneic versus syngeneic mesenchymal stem cell transplantation in MRL/lpr and (NZB/NZW)F1 mice. Clin Immunol 2012, 145:142-152.
95. Wang D., Zhang H., Liang J., Li X., Feng X., Wang H., et al. Allogeneic mesenchymal stem cell transplantation in severe and refractory systemic lupus erythematosus: 4 years experience. Cell Transplant 2013, 22:2267-2277.
96. Carrion F., Nova E., Ruiz C., Diaz F., Inostroza C., Rojo D., et al. Autologous mesenchymal stem cell treatment increased T regulatory cells with no effect on disease activity in two systemic lupus erythematosus patients. Lupus 2010, 19:317-322.
97. Matucci-Cerinic M., Kahaleh B., Wigley F.M. Review: evidence that systemic sclerosis is a vascular disease. Arthritis Rheum 2013, 65:1953-1962.
98. Larghero J., Farge D., Braccini A., Lecourt S., Scherberich A., Foïs E., et al. Phenotypical and functional characteristics of in vitro expanded bone marrow mesenchymal stem cells from patients with systemic sclerosis. Ann Rheum Dis 2008, 67:443-449.
99. Cipriani P., Guiducci S., Miniati I., Cinelli M., Urbani S., Marrelli A., et al. Impairment of endothelial cell differentiation from bone marrow-derived mesenchymal stem cells: new insight into the pathogenesis of systemic sclerosis. Arthritis Rheum 2007, 56:1994-2004.
100. Del Papa N., Quirici N., Soligo D., Scavullo C., Cortiana M., Borsotti C., et al. Bone marrow endothelial progenitors are defective in systemic sclerosis. Arthritis Rheum 2006, 54:2605-2615.
101. Cipriani P., Marrelli A., Benedetto P.D., Liakouli V., Carubbi F., Ruscitti P., et al. Scleroderma Mesenchymal Stem Cells display a different phenotype from healthy controls; implications for regenerative medicine. Angiogenesis 2013, 16:595-607.
102. Guiducci S., Manetti M., Romano E., Mazzanti B., Ceccarelli C., Dal Pozzo S., et al. Bone marrow-derived mesenchymal stem cells from early diffuse systemic sclerosis exhibit a paracrine machinery and stimulate angiogenesis in vitro. Ann Rheum Dis 2011, 70:2011-2021.
103. Cipriani P., Di Benedetto P., Liakouli V., Del Papa B., Di Padova M., Di Ianni M., et al. Mesenchymal stem cells (MSCs) from scleroderma patients (SSc) preserve their immunomodulatory properties although senescent and normally induce T regulatory cells (Tregs) with a functional phenotype: implications for cellular-based therapy. Clin Exp Immunol 2013, 173:195-206.
104. Christopeit M., Schendel M., Föll J., Müller L.P., Keysser G., Behre G. Marked improvement of severe progressive systemic sclerosis after transplantation of mesenchymal stem cells from an allogeneic haploidentical-related donor mediated by ligation of CD137L. Leukemia 2008, 22:1062-1064.
105. Guiducci S., Porta F., Saccardi R., Guidi S., Ibba-Manneschi L., Manetti M., et al. Autologous mesenchymal stem cells foster revascularization of ischemic limbs in systemic sclerosis: a case report. Ann Intern Med 2010, 153:650-654.
106. Keyszer G., Christopeit M., Fick S., Schendel M., Taute B.M., Behre G., et al. Treatment of severe progressive systemic sclerosis with transplantation of mesenchymal stromal cells from allogeneic related donors: report of five cases. Arthritis Rheum 2011, 63:2540-2542.
107. Scuderi N., Ceccarelli S., Onesti M.G., Fioramonti P., Guidi C., Romano F., et al. Human adipose-derived stromal cells for cell-based therapies in the treatment of systemic sclerosis. Cell Transplant 2013, 22:779-795.
108. Naraghi K., van Laar J.M. Update on stem cell transplantation for systemic sclerosis: recent trial results. Curr Rheumatol Rep 2013, 15:326.
109. Byers P.H., Wallis G.A., Willing M.C. Osteogenesis imperfecta: translation of mutation to phenotype. J Med Genet 1991, 28:433-442.
110. Cabral W.A., Marini J.C. High proportion of mutant osteoblasts is compatible with normal skeletal function in mosaic carriers of osteogenesis imperfecta. Am J Hum Genet 2004, 74:752-760.
111. Pereira R.F., O'Hara M.D., Laptev A.V., Halford K.W., Pollard M.D., Class R., et al. Marrow stromal cells as a source of progenitor cells for nonhematopoietic tissues in transgenic mice with a phenotype of osteogenesis imperfecta. Proc Natl Acad Sci USA 1998, 95:1142-1147.
112. Guillot P.V., Abass O., Bassett J.H., Shefelbine S.J., Bou-Gharios G., Chan J., et al. Intrauterine transplantation of human fetal mesenchymal stem cells from first-trimester blood repairs bone and reduces fractures in osteogenesis imperfecta mice. Blood 2008, 111:1717-1725.
113. Caplan A.I. Osteogenesis imperfecta, rehabilitation medicine, fundamental research and mesenchymal stem cells. Connect Tissue Res 1995, 31:S9-14.
114. Horwitz E.M., Prockop D.J., Fitzpatrick L.A., Koo W.W., Gordon P.L., Neel M., et al. Transplantability and therapeutic effects of bone marrow-derived mesenchymal cells in children with osteogenesis imperfecta. Nat Med 1999, 5:309-313.
115. Horwitz E.M., Gordon P.L., Koo W.K., Marx J.C., Neel M.D., McNall R.Y., et al. Isolated allogeneic bone marrow-derived mesenchymal cells engraft and stimulate growth in children with osteogenesis imperfecta: Implications for cell therapy of bone. Proc Natl Acad Sci USA 2002, 99:8932-8937.
116. Le Blanc K., Götherström C., Ringdén O., Hassan M., McMahon R., Horwitz E., et al. Fetal mesenchymal stem-cell engraftment in bone after in utero transplantation in a patient with severe osteogenesis imperfecta. Transplantation 2005, 79:1607-1614.
117. Millington-Ward S., McMahon H.P., Allen D., Tuohy G., Kiang A.S., PalfiA., et al. RNAi of COL1A1 in mesenchymal progenitor cells. Eur J Hum Genet 2004, 12:864-866.
118. Amanatullah D.F., Strauss E.J., Di Cesare P.E. Current management options for osteonecrosis of the femoral head: part 1, diagnosis and nonoperative management. Am J Orthop (Belle Mead NJ) 2011, 40:E186-E192.
119. Amanatullah D.F., Strauss E.J., Di Cesare P.E. Current management options for osteonecrosis of the femoral head: part II, operative management. Am J Orthop (Belle Mead NJ) 2011, 40:E216-E225.
120. Matsuya H., Kushida T., Asada T., Umeda M., Wada T., Iida H. Regenerative effects of transplanting autologous mesenchymal stem cells on corticosteroid-induced osteonecrosis in rabbits. Mod Rheumatol 2008, 18:132-139.
121. Yan Z., Hang D., Guo C., Chen Z. Fate of mesenchymal stem cells transplanted to osteonecrosis of femoral head. J Orthop Res 2009, 27:442-446.
122. Peng J., Wen C., Wang A., Wang Y., Xu W., Zhao B., et al. Micro-CT-based bone ceramic scaffolding and its performance after seeding with mesenchymal stem cells for repair of load-bearing bone defect in canine femoral head. J Biomed Mater Res B Appl Biomater 2011, 96:316-325.
123. Feitosa M.L., Fadel L., Beltrão-Braga P.C., Wenceslau C.V., Kerkis I., Kerkis A., et al. Successful transplant of mesenchymal stem cells in induced osteonecrosis of the ovine femoral head: preliminary results. Acta Cir Bras 2010, 25:416-422.
124. Noël D., Djouad F., Jorgense C. Regenerative medicine through mesenchymal stem cells for bone and cartilage repair. Curr Opin Investig Drugs 2002, 3:1000-1004.
125. Kuo T.K., Ho J.H., Lee O.K. Mesenchymal stem cell therapy for nonmusculoskeletal diseases: emerging applications. Cell Transplant 2009, 18:1013-1028.
126. Wen Q., Zhou L., Zhou C., Zhou M., Luo W., Ma L. Change in hepatocyte growth factor concentration promote mesenchymal stem cell-mediated osteogenic regeneration. J Cell Mol Med 2012, 16:1260-1273.
127. Tang T.T., Lu B., Yue B., Xie X.H., Xie Y.Z., Dai K.R., et al. Treatment of osteonecrosis of the femoral head with hBMP-2-gene-modified tissue-engineered bone in goats. J Bone Joint Surg Br 2007, 89:127-129.
128. Chan T.W., Dalinka M.K., Steinberg M.E., Kressel H.Y. MRI appearance of femoral head osteonecrosis following core decompression and bone grafting. Skeletal Radiol 1991, 20:103-107.
129. Gangji V., Hauzeur J.P., Matos C., De Maertelaer V., Toungouz M., Lambermont M. Treatment of osteonecrosis of the femoral head with implantation of autologous bone-marrow cells. A pilot study. J Bone Joint Surg Am 2004, 86-A:1153-1160.
130. Wang B.L., Sun W., Shi Z.C., Zhang N.F., Yue D.B., Guo W.S., et al. Treatment of nontraumatic osteonecrosis of the femoral head with the implantation of core decompression and concentrated autologous bone marrow containing mononuclear cells. Arch Orthop Trauma Surg 2010, 130:859-865.
131. Gangji V., De Maertelaer V., Hauzeur J.P. Autologous bone marrow cell implantation in the treatment of non-traumatic osteonecrosis of the femoral head: Five year follow-up of a prospective controlled study. Bone 2011, 49:1005-1009.
132. Zhao D., Cui D., Wang B., Tian F., Guo L., Yang L., et al. Treatment of early stage osteonecrosis of the femoral head with autologous implantation of bone marrow-derived and cultured mesenchymal stem cells. Bone 2012, 50:325-330.
133. Pak J. Autologous adipose tissue-derived stem cells induce persistent bone-like tissue in osteonecrotic femoral heads. Pain Physician 2012, 15:75-85.
134. Veronesi F., Torricelli P., Borsari V., Tschon M., Rimondini L., Fini M. Mesenchymal stem cells in the aging and osteoporotic population. Crit Rev Eukaryot Gene Expr 2011, 21:363-377.
135. Dalle Carbonare L., Valenti M.T., Zanatta M., Donatelli L., Lo Cascio V. Circulating mesenchymal stem cells with abnormal osteogenic differentiation in patients with osteoporosis. Arthritis Rheum 2009, 60:3356-3365.
136. Rosen C.J., Ackert-Bicknell C., Rodriguez J.P., Pino A.M. Marrow fat and the bone microenvironment: developmental, functional and pathological implications. Crit Rev Eukaryot Gene Expr 2009, 19:109-124.
137. Stenderup K., Justesen J., Eriksen E.F., Rattan S.I.S., Kassem M. Number and proliferative capacity of osteogenic stem cells are maintained during aging and patients with osteoporosis. J Bone Miner Res 2001, 16:1120-1129.
138. Astudillo P., Rios S., Pastenes L., Pino A.M., Rodriguez J.P. Increased adipogenesis of osteoporotic human-mesenchymal stem cells (MSCs) is characterized by impaired leptin action. J Cell Biochem 2008, 103:1054-1065.
139. Bruder S.P., Fink D.J., Caplan A.I. Mesenchymal stem cells in bone development, bone repair, and skeletal regeneration therapy. J Cell Biochem 1994, 56:283-294.
140. Wang Z., Goh J., De Das S., Ge Z., Ouyang H., Chong J.S., et al. EH Efficacy of bone marrow-derived stem cells in strengthening osteoporotic bone in a rabbit model. Tissue Eng 2006, 12:1753-1761.
141. Ocarino Nde M., Boeloni J.N., Jorgetti V., Gomes D.A., Goes A.M., Serakides R. Intra-bone marrow injection of mesenchymal stem cells improves the femur bone mass of osteoporotic female rats. Connect Tissue Res 2010, 51:426-433.
142. Nuttall M.E., Patton A.J., Olivera D.J., Nadeau D.P., Gowen M. Human trabecular bone cells are able to express both osteoblastic and adipocytic phenotype: implications for osteopenic disorders. J Bone Miner Res 1998, 13:371-382.
143. Kanakaris N.K., Petsatodis G., Tagil M., Giannoudis P.V. Is there a role for bone morphogenetic proteins in osteoporotic fractures?. Injury 2009, 40(Suppl 3):S21-S26.
144. Kim D., Cho S.W., Her S.J., Yang J.Y., Kim S.W., Kim S.Y., et al. Retrovirus-mediated gene transfer of receptor activator of nuclear factor-kappaB-Fc prevents bone loss in ovariectomized mice. Stem Cells 2006, 24:1798-1805.
145. Lien C.Y., Chih-Yuan Ho K., Lee O.K., Blunn G.W., Su Y. Restoration of bone mass and strength in glucocorticoid-treated mice by systemic transplantation of CXCR4 and cbfa-1 coexpressing mesenchymal stem cells. J Bone Miner Res 2009, 24:837-848.
146. Chen H.T., Lee M.J., Chen C.H., Chuang S.C., Chang L.F., Ho M.L., et al. Proliferation and differentiation potential of human adipose-derived mesenchymal stem cells isolated from elderly patients with osteoporotic fractures. J Cell Mol Med 2012, 16:582-593.
147. Maumus M., Guérit D., Toupet K., Jorgensen C., Noël D. Mesenchymal stem cell-based therapies in regenerative medicine: applications in rheumatology. Stem Cell Res Ther 2011, 2:14.
148. MacFarlane R.J., Graham S.M., Davies P.S., Korres N., Tsouchnica H., Heliotis M., et al. Anti-inflammatory role and immunomodulation of mesenchymal stem cells in systemic joint diseases: potential for treatment. Expert Opin Ther Targets 2013, 17:243-254.